Chen‐Yen Lin

2.3k citations

54 papers · 1.7k · 2 hit papers · h-index 20

Impact in

Rheumatology top 1%
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
Immunology top 5%
- Psoriasis: Treatment and Pathogenesis

Papers in

Immunology 23
- Psoriasis: Treatment and Pathogenesis 23
Rheumatology 22
- Spondyloarthritis Studies and Treatments 18
- Rheumatoid Arthritis Research and Therapies 9

Co-authors: Susan Halabi (5 shared papers)Catherine L Shuler (8 shared papers)Philip J. Mease (7 shared papers)Eric J. Small (2 shared papers)Ellen B. Kaplan (2 shared papers)Chin H. Lee (2 shared papers)Masato Okada (4 shared papers)Daniel Braun (1 shared paper)
Journals: Annals of the Rheumatic Diseases (8 papers)Journal of the European Academy of Dermatology and Venereology (3 papers)Journal of Dermatological Treatment (3 papers)British Journal of Dermatology (2 papers)Statistics in Medicine (2 papers)
Partner nations: United States Canada Japan

In The Last Decade

Chen‐Yen Lin

54 papers receiving 1.7k citations

Chen‐Yen Lin's Hit Papers

align trajectories log scale

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 2016 · 439 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Annals of the Rheumatic Diseases
2014 Journal of Clinical Oncology

Peers

Countries citing papers authored by Chen‐Yen Lin

Since Specialization

Citations

This map shows the geographic impact of Chen‐Yen Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chen‐Yen Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chen‐Yen Lin more than expected).

Fields of papers citing papers by Chen‐Yen Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chen‐Yen Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chen‐Yen Lin. The network helps show where Chen‐Yen Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside Chen‐Yen Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chen‐Yen Lin Line = papers co-authored together Chen‐Yen Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 Annals of the Rheumatic Diseases ·Philip J. Mease, Désirée van der Heijde, (unknown), Masato Okada, Raquel Cuchacovich, Catherine L Shuler, Chen‐Yen Lin, Daniel Braun, Chin H. Lee, Dafna Gladman Hit paper breakdown →	2016	439
2	Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology ·Susan Halabi, Chen‐Yen Lin, William K. Kelly, Karim Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, Eric J. Small Hit paper breakdown →	2014	329
3	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis British Journal of Dermatology ·Caitriona Ryan, Alan Menter, Lyn Guenther, Andrew Blauvelt, Robert Bissonnette, K.A.P. Meeuwis, John Sullivan, Jennifer Clay Cather, Gil Yosipovitch, Alice B. Gottlieb, Joseph F. Merola, Kristina Callis Duffin, Scott Fretzin, Olawale Osuntokun, Russel Burge, April N. Naegeli, Fan Emily Yang, Chen‐Yen Lin, Kris Todd, Alison Potts Bleakman, (unknown)	2018	87
4	Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis British Journal of Dermatology ·Alexa B. Kimball, April N. Naegeli, Emily Edson‐Heredia, Chen‐Yen Lin, C. Gaich, E. Nikaï, Kathleen W. Wyrwich, Gil Yosipovitch	2016	77
5	Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy Journal of Clinical Oncology ·Susan Halabi, Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Ellen B. Kaplan, Chen‐Yen Lin, Nicole Solomon, Eric J. Small	2013	74
6	Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2) American Journal of Clinical Dermatology ·Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair, Taisuke Ito, Yves Dutronc, Chen‐Yen Lin, Guanglei Yu, Chiara Chiasserini, Jill Shwed McCollam, Wen-Shuo Wu, Brett King	2023	73
7	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials Dermatology and Therapy ·Craig L. Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, C.E.M. Griffiths, Hany Elmaraghy, Heidi M. Crane, Himanshu J. Patel, Russel Burge, Gaia Gallo, David Shrom, Ann N. Leung, Chen‐Yen Lin, Kim Papp	2020	47
8	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Alice B. Gottlieb, Akimichi Morita, Joseph F. Merola, Chen‐Yen Lin, Julie Birt, Catherine L Shuler, Matthew M. Hufford, Diamant Thaçi	2019	38
9	Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab Journal of the American Academy of Dermatology ·Andrew Blauvelt, Nianwen Shi, Russel Burge, William N. Malatestinic, Chen‐Yen Lin, Carolyn R. Lew, Nicole M. Zimmerman, Orin M. Goldblum, Baojin Zhu, Mwangi J. Murage	2019	37
10	WinBasin: Using improved algorithms and the GIS technique for automated watershed modelling analysis from digital elevation models International Journal of Geographical Information Systems ·Wei-Kuan Lin, Wen‐Chien Chou, Chen‐Yen Lin, Po Huang, J.S.H. Tsai	2008	37
11	Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients Journal of the European Academy of Dermatology and Venereology ·Jashin J. Wu, Chen‐Yen Lin, L. Sun, Orin M. Goldblum, Art Zbrozek, Russel Burge, Matthias Augustin, Steven R. Feldman	2018	33
12	A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire Rheumatology and Therapy ·William Tillett, Chen‐Yen Lin, Art Zbrozek, Aubrey Trevelin Sprabery, Julie Birt	2019	33
13	Analyzing gameplay data to inform feedback loops in The Radix Endeavor Computers & Education ·Meng‐Tzu Cheng, Louisa Rosenheck, Chen‐Yen Lin, Eric Klopfer	2017	31
14	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1) Lara D. Veeken ·Alice B. Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, Philip J. Mease, Diamant Thaçi, Julie Birt, Chin H. Lee, Catherine L Shuler, Chen‐Yen Lin, Dafna D. Gladman	2018	27
15	Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization BMC Dermatology ·April W. Armstrong, Shonda A. Foster, Brian S. Comer, Chen‐Yen Lin, William N. Malatestinic, Russel Burge, Orin M. Goldblum	2018	26
16	Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1 RMD Open ·Laura C. Coates, Mitsumasa Kishimoto, Alice B. Gottlieb, Catherine L Shuler, Chen‐Yen Lin, Chin Hyok Lee, Philip J. Mease	2017	24
17	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. PubMed ·Arthur Kavanaugh, Helena Marzo‐Ortega, Ronald Vender, James Cheng‐Chung Wei, Julie Birt, David H. Adams, Olivier Bénichou, Chen‐Yen Lin, Peter Nash	2019	23
18	<p>Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab</p> Patient Preference and Adherence ·Andrew Blauvelt, Nianwen Shi, Russel Burge, William N. Malatestinic, Chen‐Yen Lin, Carolyn R. Lew, Nicole M. Zimmerman, Orin M. Goldblum, Baojin Zhu, Mwangi J. Murage	2020	22
19	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension Acta Dermato Venereologica ·Alexa B. Kimball, Thomas A. Luger, Alice B. Gottlieb, L. Puig, Roland Kaufmann, RT Burge, Chen‐Yen Lin, Gil Yosipovitch	2017	22
20	Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials Journal of the European Academy of Dermatology and Venereology ·C. Paul, Lyn Guenther, Hideshi Torii, Howard Sofen, Russel Burge, Chen‐Yen Lin, Alison Potts Bleakman, Lotus Mallbris, Yves Poulin	2017	19

About Chen‐Yen Lin

Chen‐Yen Lin is a scholar working on Immunology, Rheumatology, Statistics and Probability, Dermatology and Hematology, having authored 54 papers that have together received 1.7k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (23 papers), Spondyloarthritis Studies and Treatments (18 papers), Rheumatoid Arthritis Research and Therapies (9 papers), Statistical Methods in Clinical Trials (5 papers), Dermatology and Skin Diseases (4 papers), Statistical Methods and Inference (4 papers), Autoimmune and Inflammatory Disorders Research (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). The work is most often cited by research in Rheumatology (512 citations), Immunology (655 citations), Dermatology (238 citations), Hematology (176 citations) and Urology (65 citations). Chen‐Yen Lin has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Susan Halabi, Catherine L Shuler, Philip J. Mease, Eric J. Small, Ellen B. Kaplan, Chin H. Lee, Masato Okada, Daniel Braun, Dafna Gladman and Raquel Cuchacovich. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of the European Academy of Dermatology and Venereology, Journal of Dermatological Treatment, British Journal of Dermatology and Statistics in Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Chen‐Yen Lin

Impact in

Papers in i

In The Last Decade

Chen‐Yen Lin

Chen‐Yen Lin's Hit Papers

Peers

Countries citing papers authored by Chen‐Yen Lin

Fields of papers citing papers by Chen‐Yen Lin

All Works

About Chen‐Yen Lin

Explore authors with similar magnitude of impact

Papers in